- BioCryst Pharmaceuticals ( NASDAQ: BCRX ) is collaborating with Swixx BioPharma to commercialize hereditary angioedema attack (HAE) prevention therapy Orladeyo (berotralstat) in Central and Eastern Europe (CEE).
- HAE is a disorder characterized by recurrent episodes (attacks) of severe swelling of the skin and mucous membranes.
- Under the agreement , Swixx will be responsible for commercializing the drug in 15 markets within CEE.
- "The team at Swixx is highly skilled at launching rare disease therapies in Central and Eastern Europe, and we are thrilled to work alongside them to bring our oral, once-daily prophylactic treatment for HAE to patients in this region," said BioCryst's Chief Commercial Officer Charlie Gayer.
- BCRX -2.98% to $10.09 premarket Jan. 23
For further details see:
BioCryst teams up with Swixx to sell Orladeyo in Central, Eastern Europe